Zegerid OTC, Private Label Omeprazole Add Drug Interaction Warnings
This article was originally published in The Tan Sheet
CDER approves sNDAs from Bayer for Zegerid OTC powder and private label manufacturer Dexcel Pharma for omeprazole delayed release tablets to add label warnings on drug-drug interactions for methotrexate and mycophenolate mofetil.
You may also be interested in...
Public Citizen petitions FDA to add several warnings to all proton pump inhibitors, including OTCs – which the agency previously determined do not pose the same level of risk as prescription versions.
Reps. Brendan Boyle and Darin LaHood introduce Dietary Supplement Tax Fairness Ac to amend Internal Revenue Code to include some supplement products as qualified medical expenses.
Using web app for self-selection was successful with more than 95% concordance for the primary endpoint comparing results obtained by participants and independent clinical assessments, say researchers led by cardiologist and consumer health innovation advocate Steven Nissen.